{"id":7746,"date":"2021-03-01T10:09:12","date_gmt":"2021-03-01T09:09:12","guid":{"rendered":"https:\/\/www.iqac.csic.es\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/"},"modified":"2026-06-16T11:11:10","modified_gmt":"2026-06-16T09:11:10","slug":"research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia","status":"publish","type":"post","link":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/","title":{"rendered":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Within all the research lines carried out at the <strong>Institute for Advanced Chemistry of Catalonia<\/strong> of the <a href=\"https:\/\/www.csic.es\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Spanish National Research Council (CSIC)<\/strong><\/a>, seven research groups dedicate part of their efforts to the study &#8220;Rare Diseases&#8221;.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Rare diseases are diseases which affect a small number of people compared to the general population and specific issues are raised in relation to their rarity. In Europe, a disease is considered to be rare when it affects 5 people per 10,000. Therefore, they are rare disorders or conditions that affect a small part of the population, but which in global terms affect 26 million people in Europe, and therefore constitute a global health problem. To date there are 6,172 rare diseases described.<\/span><\/p>\n<p><a href=\"https:\/\/www.rarediseaseday.org\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Rare Disease Day<\/span><\/a><span style=\"font-weight: 400;\"> has been celebrated on the last day of February, since 2008. The date was chosen because February is a \u201crare month\u201d, and for this particular characteristic the last day of Febreary was chosen to associate this rarity with the disease.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">With the aim of making this type of disease more visible, the IQAC-CSIC joins the commemoration of this day by explaining the latest advances in the field.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/surfactants-and-nanobiotechnology\/nucleic-acids-chemistry\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Nucleic Acid Chemistry group<\/span><\/a><span style=\"font-weight: 400;\"> led by the researcher <\/span><b>Ramon Eritja<\/b><span style=\"font-weight: 400;\">, advises the group of <\/span><b>Drs. R. Artero<\/b><span style=\"font-weight: 400;\"> and <\/span><b>B. Llamus\u00ed<\/b><span style=\"font-weight: 400;\"> on a Prometheus project of the Generalitat Valenciana, which aims to develop oligonucleotides that serve for the treatment of <\/span><b>myotonic dystrophy type 1<\/b><span style=\"font-weight: 400;\"> or <\/span><b>Steinert&#8217;s myotonic dystrophy<\/b><span style=\"font-weight: 400;\">. It is a serious, degenerative neuromuscular disease that can affect various systems such as the muscular, respiratory, cardiac, endocrine, ocular and central nervous system. Among its most characteristic symptoms is muscle weakness, which together with cardiac arrhythmias are its main causes of mortality. This disease, which currently suffers from 90,000 Europeans, and which affects children and adults alike, still does not have an effective treatment, although a first candidate for clinical studies has already been obtained.<\/span><\/p>\n<p><b>Ramon Crehuet<\/b><span style=\"font-weight: 400;\">, belonging to the <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/biological-chemistry\/theoretical-and-computational-chemistry\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Theoretical and Computational Chemistry group<\/span><\/a><span style=\"font-weight: 400;\">, works with a neurodegenerative disease, called <\/span><b>Kennedy disease<\/b><span style=\"font-weight: 400;\"> or <\/span><b>spinobulbar muscular atrophy<\/b><span style=\"font-weight: 400;\">. It is part of the family of polyglutamine disorders to which Huntington&#8217;s disease belongs. &#8220;These disorders take place when the polyglutamine fragment of a protein exceeds a limit. These limits depend on each protein and the reason is not known \u201d, explains <\/span><b>Dr. Crehuet<\/b><span style=\"font-weight: 400;\">. &#8220;The reason why toxicity basically affects neurons, and not all cells of the body, is not known either,&#8221; the researcher clarifies. The group of Theoretical and Computational Chemistry, study the structure of the polyglutamine fragment and how the neighboring amino acids of the protein can determine the structure. This aspect is key, since the structure it adopts determines its propensity to aggregate and interact with other biomolecules, and it is in these interactions that the key to understanding its toxicity.<\/span><\/p>\n<p><b>Cystinosis <\/b><span style=\"font-weight: 400;\">is a metabolic disease characterized by the accumulation of cystine crystals (Cys2) &#8211; an oxidized dimeric form of the amino acid cysteine \u200b\u200b(Cys) -, inside the lysosomes of different organs and tissues. It is a hereditary genetic disease that can lead to different pathologies such as rickets, Fanconi syndrome, blindness, kidney failure, lung, brain or muscle dysfunction and premature death. <\/span><b>Ignacio Alfonso<\/b><span style=\"font-weight: 400;\">, <\/span><b>Jordi Sol\u00e0<\/b><span style=\"font-weight: 400;\"> and <\/span><b>Daniel Carbajo<\/b><span style=\"font-weight: 400;\">, from the <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/biological-chemistry\/supramolecular-chemistry\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Supramolecular Chemistry group<\/span><\/a><span style=\"font-weight: 400;\">, are working on the development of an inexpensive fluorescent method for the quick and easy quantification of intracellular cystine, which could complement the sophisticated methods currently used in the main hospitals. <\/span><span style=\"font-weight: 400;\">\u201c<\/span><span style=\"font-weight: 400;\">The proposal aims to carry out an evolution of the method developed and patented by our group in 2018, which selectively detects Cys and Cys2 in human urine, using a simple protocol and in just one hour\u201d, explains <\/span><b>Alfonso<\/b><span style=\"font-weight: 400;\">.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Also in the field of diagnosis, <\/span><b>Lluisa Vilaplana <\/b><span style=\"font-weight: 400;\">and <\/span><b>J.-Pablo Salvador<\/b><span style=\"font-weight: 400;\"> are focused on the development of new diagnostic systems based on antibodies, to achieve an early and rapid detection method for <\/span><b>cystic fibrosis<\/b><span style=\"font-weight: 400;\">. It is a rare genetic disease characterized by the abnormal accumulation of thick mucus in the lungs, which progressively limits respiratory capacity. This fact is associated with an important predisposition to suffer persistent infections, mainly caused by the bacterial species <\/span><i><span style=\"font-weight: 400;\">Pseudomonas aeruginosa<\/span><\/i><span style=\"font-weight: 400;\"> and <\/span><i><span style=\"font-weight: 400;\">Staphylococcus aureus<\/span><\/i><span style=\"font-weight: 400;\">. These infections are the main responsible for the high levels of mortality suffered by this type of patients, who have a life expectancy close to 45 years. &#8220;An early diagnosis is essential for a better prognosis of these diseases, and in this specific case, having early detection tools will be crucial to avoid the chronification of these infections,&#8221; explains <\/span><b>M. Pilar Marco<\/b><span style=\"font-weight: 400;\">, head of the <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/surfactants-and-nanobiotechnology\/nanobiotecnology-for-diagnostics\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Nanobiotechnology group for Diagnosis<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The advancement of nanomedicine opens up new new possibilities in the development of drugs, such as the one recently developed for the <\/span><b>rare disease Fabry<\/b><span style=\"font-weight: 400;\">, with improved efficacy compared to existing authorized treatments. This important achievement has been achieved within the European Smart4Fabry project, which is now ending after four years of work and in which researchers from the <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/surfactants-and-nanobiotechnology\/multivalent-systems-for-nanomedicine\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Multivalent Systems for Nanomedicine group,<\/span><\/a><span style=\"font-weight: 400;\"> led by <\/span><b>Miriam Royo<\/b><span style=\"font-weight: 400;\">, have participated. Fabry disease is a chronic debilitating disease due to recurrent episodes of severe pain that are difficult to control with conventional analgesics, and it is life-threatening. The newly developed drug improves current treatments and helps reduce costs and improve the quality of life of patients.<\/span><\/p>\n<p><b>Amyloidoses<\/b><span style=\"font-weight: 400;\"> associated with transthyretin are characterized by the appearance of deposits of this protein, either in its native form or in the form of a point mutant, and can affect different organs. One of them is <\/span><b>amyloid familial polyneuropathy (FAP)<\/b><span style=\"font-weight: 400;\"> or <\/span><b>Andrade&#8217;s disease<\/b><span style=\"font-weight: 400;\">, a rare hereditary disease that begins at an early age and affects the peripheral nervous system. To date, one of the therapeutic strategies to treat this disease is based on the stabilization of the native state of transthyretin with small molecules. The <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/biological-chemistry\/unit-of-glycoconjugate-chemistry\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Glycoconjugate Chemistry Unit<\/span><\/a><span style=\"font-weight: 400;\"> has focused its research on a drug discovery project to treat this type of transthyretin-related amyloidosis. &#8220;The interdisciplinary project has been funded by the Fundaci\u00f3 Marat\u00f3 de TV3&#8221;, explains <\/span><b>Gemma Arsequel<\/b><span style=\"font-weight: 400;\">l, head of the Unit.<\/span><\/p>\n<p><b>Gemma Fabri\u00e0s<\/b><span style=\"font-weight: 400;\">,<\/span><b> Josefina Casas<\/b><span style=\"font-weight: 400;\">, <\/span><b>Jos\u00e9 Lus Abad<\/b><span style=\"font-weight: 400;\"> and Antonio Delgado, from the <\/span><a href=\"https:\/\/www.iqac.csic.es\/research\/departments\/biological-chemistry\/research-unit-on-bioactive-molecules\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Bioactive Molecules Research Unit<\/span><\/a><span style=\"font-weight: 400;\">, also work developing diagnostic tools for different types of rare diseases. Both <\/span><b>Farber&#8217;s disease<\/b><span style=\"font-weight: 400;\"> and the<\/span><b> syndrome of spinal muscular atrophy with progressive myoclonic epilepsy <\/b><span style=\"font-weight: 400;\">are caused by mutations in the ASAH1 gene, which encodes acid ceramidase. In this case, they are working on the development of compounds that allow the activity of this enzyme to be measured quickly, easily and robustly directly on cells from patients.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Another research line is focused on hereditary movement disorders, such as<\/span><b> spastic paraparesis<\/b><span style=\"font-weight: 400;\">, <\/span><b>cerebellar ataxias<\/b><span style=\"font-weight: 400;\">, or<\/span><b> peripheral neuropathies<\/b><span style=\"font-weight: 400;\">. The lipid metabolism is deregulated in this spectrum of diseases, so they try to carry out the characterization of the lipids of the patients&#8217; cells in order to identify biomarkers and therapeutic targets. Lastly, they work on the treatment of<\/span><b> Niemann Pick A \/ B disease<\/b><span style=\"font-weight: 400;\">. It is a group of inherited diseases, in which lipids accumulate in the cells of the spleen, liver and brain. Currently, the existing therapy is enzyme replacement, but this therapy is not always useful, so they are focused on finding a therapy based on pharmacological chaperones.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Much remains to be done, but fortunately, more and more research groups and funding are dedicated to the study of rare diseases. This is totally necessary since it is important to emphasize that although the prevalence of these pathologies is low, it affects millions of people around the world and is a serious global health problem.<\/span><\/p>\n<p style=\"text-align: right;\"><b>IQAC-CSIC Communication<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Within all the research lines carried out at the Institute for Advanced Chemistry of Catalonia of the Spanish National Research Council (CSIC), seven research groups dedicate part of their efforts to the study &#8220;Rare Diseases&#8221;. Rare diseases are diseases which affect a small number of people compared to the general population and specific issues are<a class=\"more-link\" href=\"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/\">Continue reading <span class=\"screen-reader-text\">&#8220;Research on rare diseases at the Institute for Advanced Chemistry of Catalonia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":3665,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-7746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"og:description\" content=\"Within all the research lines carried out at the Institute for Advanced Chemistry of Catalonia of the Spanish National Research Council (CSIC), seven research groups dedicate part of their efforts to the study &#8220;Rare Diseases&#8221;. Rare diseases are diseases which affect a small number of people compared to the general population and specific issues areContinue reading &quot;Research on rare diseases at the Institute for Advanced Chemistry of Catalonia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/\" \/>\n<meta property=\"og:site_name\" content=\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/iqac.csic.es\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T09:09:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T09:11:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"901\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana Sotres\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:site\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Sotres\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/\"},\"author\":{\"name\":\"Ana Sotres\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/person\\\/ac65d00561d3a6d2810128c46771aff7\"},\"headline\":\"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia\",\"datePublished\":\"2021-03-01T09:09:12+00:00\",\"dateModified\":\"2026-06-16T09:11:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/\"},\"wordCount\":1248,\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/5804963.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/\",\"name\":\"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/5804963.jpg\",\"datePublished\":\"2021-03-01T09:09:12+00:00\",\"dateModified\":\"2026-06-16T09:11:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/5804963.jpg\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/5804963.jpg\",\"width\":1600,\"height\":901},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"description\":\"Chemistry for a better life\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.iqac.csic.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"width\":512,\"height\":512,\"caption\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/iqac.csic.es\\\/\",\"https:\\\/\\\/x.com\\\/IQAC_CSIC\",\"https:\\\/\\\/www.instagram.com\\\/iqac_csic\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC1JXTOe3-s8UnYu_A6-SI3A\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/iqac-csic\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/person\\\/ac65d00561d3a6d2810128c46771aff7\",\"name\":\"Ana Sotres\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"caption\":\"Ana Sotres\"},\"sameAs\":[\"https:\\\/\\\/www.iqac.csic.es\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/","og_locale":"en_US","og_type":"article","og_title":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","og_description":"Within all the research lines carried out at the Institute for Advanced Chemistry of Catalonia of the Spanish National Research Council (CSIC), seven research groups dedicate part of their efforts to the study &#8220;Rare Diseases&#8221;. Rare diseases are diseases which affect a small number of people compared to the general population and specific issues areContinue reading \"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia\"","og_url":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/","og_site_name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","article_publisher":"https:\/\/www.facebook.com\/iqac.csic.es\/","article_published_time":"2021-03-01T09:09:12+00:00","article_modified_time":"2026-06-16T09:11:10+00:00","og_image":[{"width":1600,"height":901,"url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg","type":"image\/jpeg"}],"author":"Ana Sotres","twitter_card":"summary_large_image","twitter_creator":"@IQAC_CSIC","twitter_site":"@IQAC_CSIC","twitter_misc":{"Written by":"Ana Sotres","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#article","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/"},"author":{"name":"Ana Sotres","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/person\/ac65d00561d3a6d2810128c46771aff7"},"headline":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia","datePublished":"2021-03-01T09:09:12+00:00","dateModified":"2026-06-16T09:11:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/"},"wordCount":1248,"publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"image":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/","url":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/","name":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#primaryimage"},"image":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg","datePublished":"2021-03-01T09:09:12+00:00","dateModified":"2026-06-16T09:11:10+00:00","breadcrumb":{"@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#primaryimage","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/5804963.jpg","width":1600,"height":901},{"@type":"BreadcrumbList","@id":"https:\/\/www.iqac.csic.es\/en\/research-on-rare-diseases-at-the-institute-for-advanced-chemistry-of-catalonia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.iqac.csic.es\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Research on rare diseases at the Institute for Advanced Chemistry of Catalonia"}]},{"@type":"WebSite","@id":"https:\/\/www.iqac.csic.es\/#website","url":"https:\/\/www.iqac.csic.es\/","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","description":"Chemistry for a better life","publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.iqac.csic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.iqac.csic.es\/#organization","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","url":"https:\/\/www.iqac.csic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","width":512,"height":512,"caption":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC"},"image":{"@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/iqac.csic.es\/","https:\/\/x.com\/IQAC_CSIC","https:\/\/www.instagram.com\/iqac_csic","https:\/\/www.youtube.com\/channel\/UC1JXTOe3-s8UnYu_A6-SI3A","https:\/\/www.linkedin.com\/company\/iqac-csic\/"]},{"@type":"Person","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/person\/ac65d00561d3a6d2810128c46771aff7","name":"Ana Sotres","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","caption":"Ana Sotres"},"sameAs":["https:\/\/www.iqac.csic.es\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/posts\/7746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/comments?post=7746"}],"version-history":[{"count":1,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/posts\/7746\/revisions"}],"predecessor-version":[{"id":8594,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/posts\/7746\/revisions\/8594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/media\/3665"}],"wp:attachment":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/media?parent=7746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/categories?post=7746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/tags?post=7746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}